Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Chronic radiation-induced dermatitis: what is new in 2024? A narrative review

Siedlecki E., Remiszewski P., Spałek MJ.

Narrative Review on Systemic / IV, published in Rep Pract Oncol Radiother (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Rep Pract Oncol Radiother (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42131457
PMCID
PMC13167004
DOI
10.5603/rpor.110468

Abstract (original English)

Radiation exposure can cause two main types of dermatitis: acute radiation dermatitis (ARD) and chronic radiation dermatitis (CRD). ARD appears days to weeks after exposure, with symptoms including redness, peeling, and blistering. At the same time, CRD develops over months to years, resulting in long-lasting skin changes such as fibrosis, pigmentation, and telangiectasia. Most studies on radiation dermatitis focus on ARD, yet doctors must update their knowledge about CRD, as it affects approximately one-third of patients. This review aims to present the current knowledge of CRD as an update to our previous work published in 2016. We focused mainly on the latest advancements and challenges in its prevention, diagnosis, and treatment as of 2024. It is even more critical to treat CRD effectively, as during the last eight years, the life expectancy of oncologic patients has significantly improved. Recent studies unraveled much about the pathophysiological mechanisms behind CRD, including the roles of micro ribonucleoacids (miRNAs), epigenetic factors, and epithelial-mesenchymal transition. Innovations in radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT) and personalized protective shields, have reduced the incidence and severity of CRD. New pharmacological interventions, including topical agents and systemic medications, can manage symptoms like erythem

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research